Immune Pharmaceuticals : Appoints Paul Nadler, MD, EVP, R&D and Chief Medical Officer

NEW YORK , Feb. 9, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced the appointment Dr. Paul Nadler as acting Executive Vice President, Research & Development and Chief Medical Officer. In this position, Dr. Nadler will be responsible for overseeing the development of IMMUNE's immunology and oncology pipeline.

Dr. Nadler commented: "I am excited about the opportunity to work with Immune Pharmaceuticals at this important inflexion point with the development of bertilimumab. The target for bertilimumab, eotaxin-1, may play a key role in multiple auto-immune and inflammatory diseases. We look forward to data from the phase II clinical trial in bullous pemphigoid in 2015 and data from the phase II clinical trial in ulcerative colitis in 2016. I believe that additional important indications may be selected for further development based on pre-clinical and pilot clinical data and I am excited about future possibilities. In addition, I am hopeful that we will be able to evaluate and capitalize on the great potential of the existing diverse nanomAbs® platform to facilitate truly targeted delivery of a variety of active antineoplastic agents to take us beyond earlier generation nano-therapeutics and other conjugate technologies tested thus far."

"We welcome Dr. Paul Nadler to our senior management team. Dr. Nadler brings deep scientific, clinical and regulatory expertise and a successful track record that will help accelerate the development of Immune's innovative pipeline," said Immune Pharmaceuticals' CEO, Dr. Daniel Teper .

Paul I. Nadler , M.D., FCP, FACP has a long track record in basic research and clinical development of novel agents to treat patients with severe, progressive, and life-threatening diseases primarily in immunologically-mediated and inflammatory diseases, as well as oncology and virology. He has led development of successfully marketed biologicals, including cytokines and monoclonal antibodies, as well as small molecules. Since founding his own consultancy, Dr. Nadler has served as an interim or acting Chief Medical Officer/Vice President of Medical Research or Product Development for a variety of early stage biotechnology companies such as OSI Pharmaceuticals, Fast Track Systems, Alexion Pharmaceuticals, CGI Pharma, Phylogix, Aveo, Dicerna and others. Dr. Nadler has served on a variety of Medical, Oncology and Scientific Advisory Boards, and advised government agencies, academic centers, and research institutes. Previously, he served as Chief Medical Officer for Kern McNeill International; Vice President, Medical and Regulatory Affairs of Protein Design Labs, Inc. (including responsibility for preclinical development); Vice President, Scientific Planning and Analysis and Vice President, Medical Research with Sandoz Research Institute (Novartis); Vice President and Medical Director with Knoll Pharmaceuticals (now part of AbbVie); and Director of Clinical Immunology, and Head, Section of Immunology and Virology, Department of Medical Research with Hoffmann La Roche, Inc. Dr. Nadler's medical training is in Internal Medicine, Medical Oncology, as well as Clinical Immunology and Allergy. He received his M.D. from Washington University School of Medicine, trained in Internal Medicine at Barnes Hospital/Washington University Medical Center and spent five years in the Immunology Branch of the National Cancer Institute, NIH.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011 , while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca.  Immune's pipeline also includes nanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for Phase III. AmiKet has received Orphan Drug Designation for Post Herpetic Neuralgia.

For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet™ will not be successful; the risk that bertilimumab, AmiKet™ or compounds arising from our nanomAbs® program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-pharmaceuticals-appoints-paul-nadler-md-evp-rd-and-chief-medical-officer-300032652.html

SOURCE Immune Pharmaceuticals Inc.